Results 41 to 50 of about 871,553 (293)

Mechanisms of HCV resistance to broadly neutralizing antibodies

Current Opinion in Virology, 2021
Broadly neutralizing antibodies (bNAbs) block infection by genetically diverse hepatitis C virus (HCV) isolates by targeting relatively conserved epitopes on the HCV envelope glycoproteins, E1 and E2. Many amino acid substitutions conferring resistance to these bNAbs have been characterized, identifying multiple mechanisms of bNAb escape.
Nicole Frumento, Andrew I Flyak, Justin R Bailey   +2 more
openaire   +3 more sources

Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]

, 2014
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
Katja Klein, Julian K‐C. Ma, Klein, K, Ma, JK-C, Teh, AY, Ma, Julian K.C., Maresch, Daniel, Teh, AY-H, Klein, Katja, Ma, JK, Teh, Audrey Y.H., Audrey Y‐H. Teh, Daniel Maresch, Maresch, D   +13 more
core   +1 more source

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies

mBio, 2020
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner, Barnett Alfant, Jesse A. Weber, Matthew R. Gardner, Michael Farzan   +4 more
doaj   +1 more source

Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection. [PDF]

PLoS ONE, 2012
BACKGROUND: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs) during the acute/early phases of infection have been analyzed in depth in many studies.
Antoine Chaillon, Martine Braibant, Stéphane Hué, Samia Bencharif, David Enard, Alain Moreau, Assia Samri, Henri Agut, Francis Barin   +8 more
doaj   +1 more source

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition [PDF]

, 2013
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broadly neutralizing antibodies 2F5 and 4E10. To date, no immunization regimen in animals or humans has produced HIV-1 neutralizing MPER-specific antibodies ...
Ramos, Alejandra, Alexandre M. J. J. Bonvin (18079), David Lutje Hulsik, Verrips, C. Theo, Ying-ying Liu, Liu, Ying-ying, Battella, Simone, Jean-Pierre Simorre, C. Theo Verrips (200972), Miriam Hock, Miriam Hock (386536), Lucy Rutten (386540), Nika M. Strokappe (386532), Davis, David, Hinz, Andreas, Alejandra Ramos, Mohamed El Khattabi (386534), Bonvin, Alexandre M. J. J., Michael S Seaman, Rutten, Lucy, Alexandre M J J Bonvin, Simone Battella, Marlén M. I. Aasa-Chapman (208291), Pascal Poignard (244468), Sabin, Charles, Pascal Poignard, Seaman, Michael S., Anna Forsman Quigley, Pauline Macheboeuf, Seaman, Michael, Andreas Hinz (237046), Forsman Quigley, Anna, Anna Forsman Quigley (177474), Strokappe, Nika M, C Theo Verrips, Simorre, Jean-Pierre, Mohamed El Khattabi, Hulsik, David Lutje, Andreas Hinz, Winfried Weissenhorn (214542), McCoy, Laura E., Langedijk, Johannes P M, Johannes P. M. Langedijk (254439), Pauline Macheboeuf (386537), Charles Sabin, Marlén M I Aasa-Chapman, David Davis (190113), Robin A. Weiss (254468), Johannes P M Langedijk, Favier, Adrien, Lucy Rutten, Laura E. McCoy (386535), Adrien Favier (386539), Hock, Miriam, Alejandra Ramos (386538), Weiss, Robin A., Nika M Strokappe, David Lutje Hulsik (177480), Winfried Weissenhorn, Macheboeuf, Pauline, Lutje Hulsik, David, David Davis, Robin A Weiss, Aasa-Chapman, Marlén M. I., Strokappe, Nika M., Ying-ying Liu (386531), Weissenhorn, Winfried, Adrien Favier, Weiss, Robin A, Simone Battella (386533), Langedijk, Johannes P. M., Bonvin, Alexandre M J J, Michael S. Seaman (155998), Jean-Pierre Simorre (177519), El Khattabi, Mohamed, Seaman, Michael S, Aasa-Chapman, Marlén M I, Laura E McCoy, Poignard, Pascal, Verrips, C Theo, Charles Sabin (75940), Weissenhorn W, Poignard P, Hulsik, D.L., Biomolecular Imaging, el Khattabi, M., Hock M, McCoy, Laura E, McCoy LE, Simorre JP, Rutten L., Aasa-Chapman Marlén M. I., Hock Miriam, Davis David, Bonvin, A.M.J.J., Rutten Lucy, Macheboeuf P, Battella, S., Rutten, L., El Khattabi M, Battella Simone, Hinz A, Forsman Quigley A, Weiss Robin A., Langedijk JP, Lutje Hulsik D, Liu YY, Sub NMR Spectroscopy, Celbiologie, Aasa Chapman MM, Liu, Y.Y., Ramos Alejandra, Simorre Jean-Pierre, Verrips C. Theo, Ramos A, Liu Ying-ying, Sabin C, Favier A, Macheboeuf Pauline, Weiss RA, Verrips, C.T., Weissenhorn Winfried, Sub Biomolecular Imaging, Sub Cell Biology, Poignard Pascal, Davis D, Langedijk Johannes P. M., Hinz Andreas, Bonvin Alexandre M. J. J., Seaman Michael S., El Khattabi Mohamed, Bonvin AM, Dep Scheikunde, Strokappe NM, NMR Spectroscopy, Strokappe, N.M., Sabin Charles, Strokappe Nika M., Seaman MS, Lutje Hulsik David, McCoy Laura E., Verrips CT, Forsman Quigley Anna, Favier Adrien   +143 more
core   +3 more sources

Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials. [PDF]

Virol J
Background The introduction of new SARS-CoV-2 Omicron strains has made it extremely difficult to create broadly neutralizing antibodies (nAbs) with assured therapeutic potential.
Huang Y, Lin Z, Guo X, Zhang F, Wang Y, Zhang Z, Chen J, Liu L, Zhu M, Li Y, Ni M, Zhen Z, Wu Z, Ling X, Zhou S, Xi Y, Yu Y, Liang W, Zhao J, Li L, He J, Sang L.   +21 more
europepmc   +2 more sources

Broadly neutralizing antibodies target a haemagglutinin anchor epitope [PDF]

Nature, 2021
AbstractBroadly neutralizing antibodies that target epitopes of haemagglutinin on the influenza virus have the potential to provide near universal protection against influenza virus infection1. However, viral mutants that escape broadly neutralizing antibodies have been reported2,3.
Jenna J. Guthmiller, Julianna Han, Henry A. Utset, Lei Li, Linda Yu-Ling Lan, Carole Henry, Christopher T. Stamper, Meagan McMahon, George O’Dell, Monica L. Fernández-Quintero, Alec W. Freyn, Fatima Amanat, Olivia Stovicek, Lauren Gentles, Sara T. Richey, Alba Torrents de la Peña, Victoria Rosado, Haley L. Dugan, Nai-Ying Zheng, Micah E. Tepora, Dalia J. Bitar, Siriruk Changrob, Shirin Strohmeier, Min Huang, Adolfo García-Sastre, Klaus R. Liedl, Jesse D. Bloom, Raffael Nachbagauer, Peter Palese, Florian Krammer, Lynda Coughlan, Andrew B. Ward, Patrick C. Wilson   +32 more
openaire   +2 more sources

Stalking influenza by vaccination with pre-fusion headless HA mini-stem. [PDF]

, 2016
Inaccuracies in prediction of circulating viral strain genotypes and the possibility of novel reassortants causing a pandemic outbreak necessitate the development of an anti-influenza vaccine with increased breadth of protection and potential for rapid ...
Carnell, George, Temperton, Nigel J., Mallajosyula, VVA, Poon, Leo LM, Mallajosyula, V Vamsee Aditya, Temperton, N, Poon, LLM, Chin, Alex WH, Mallajosyula, VV, Chin, Alex W H, Carnell, G, Valkenburg, Sophie A, Li, OTW, Poon, Leo L M, Chin, WH, Mallajosyula, Vamsee Aditya V, Poon, LML, Li, Olive T W, Varadarajan, Raghavan, Doak, SA, Li, Olive TW, Temperton, Nigel, Chin, AWH, Valkenburg, SA, Varadarajan, R   +24 more
core   +1 more source

Antibody-mediated prevention and treatment of HIV-1 infection

Retrovirology, 2018
Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the evaluation of these antibodies in healthy and HIV-1-infected humans.
Henning Gruell, Florian Klein
doaj   +1 more source

Pseudotype-based neutralization assays for influenza: a systematic analysis [PDF]

, 2015
The use of vaccination against the influenza virus remains the most effective method of mitigating the significant morbidity and mortality caused by this virus.
Ferrara, Francesca, Keith eGrehan, Temperton, Nigel J., George William Carnell, Craig Peter Thompson, Francesca eFerrara, Nigel James Temperton, Grehan, Keith, Carnell, George W., Thompson, Craig P., Francesca Ferrara, Keith Grehan   +11 more
core   +1 more source